News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Taro Pharmaceutical Industries Ltd. (TARO) Receives Approval For Hydrocortisone Butyrate Cream USP, 0.1% ANDA; Generic Equivalent To Locoid(R) Cream



10/19/2005 5:09:05 PM

HAWTHORNE, N.Y.--(BUSINESS WIRE)--Aug. 4, 2005--Taro Pharmaceutical Industries Ltd. (Nasdaq: TARO) reported today that it has received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Hydrocortisone Butyrate Cream USP, 0.1% ("hydrocortisone butyrate cream"). Taro's hydrocortisone butyrate cream is bioequivalent to Ferndale Laboratories' Locoid(R) cream. Hydrocortisone butyrate cream is a prescription topical corticosteroid product used in managing inflammatory skin conditions. According to industry sources, U.S. sales of Locoid(R) cream were approximately $8.2 million in 2004. Taro also markets hydrocortisone butyrate ointment and topical solution products.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES